Table of Contents
The inherent instability of protein drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed – a requirement referred to as the ‘cold chain’. Alternatively, proteins can be formulated as powders (lyophilization). Lyophilized proteins must be reconstituted prior to injection. Lyophilized drugs are increasingly being sold with reconstitution vial systems, or packaged in special injection devices (e.g., pens, needle-free injectors, two-part syringes) that allow reconstitution to take place in the device prior to injection. Drug Reconstitution Systems for Self-Administration examines the impact of reconstitution at the point of self-administration on injectable drug markets.
The value we provide to our clients and subscribers is best illustrated by our ability to consistently provide strategic direction and market knowledge that contributes to their tactical and strategic decision process.
Market-driven Product Strategies
A longer life span is expected to translate to a growing number of patients diagnosed with chronic conditions. To counteract the financial and medical infrastructure implications of this trend, pressure from the public sector and managed care organizations will place a premium on therapeutic self-administration, an expectation that is creating an increased interest in routes of administration that are patient-friendly and cost-effective. Pharma company decision makers have come to the realization that for many products, success no longer only depends on the medication itself but also on achieving a consumer-compatible form of packaging and application.
What You Will Learn
What is the impact of lyophilized injectable drugs on today’s therapeutic market, and who markets them?
Who are the suppliers of point-of-care reconstitution devices, and what is their market impact?
What are the major factors driving point-of-care drug reconstitution demand?
What is the relative impact of integrated reconstitution systems to standard reconstitution devices and how will this change by the end of the decade?
What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?
What is the role of point-of-care drug reconstitution systems on drug life cycle management?
What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?
Get Industry Insights. Simply.
Talk to Amrita
+1 718 303 2019
North America Facial Injectables Market: Overview This report on the North America facial injectables market analyzes the current and future prospects of the market. The report comprises an elaborate executive ...
Global Pulmonary Drug Delivery Devices Market: Overview This report on pulmonary drug delivery devices studies the current as well as future prospects of the market globally. The stakeholders of this report ...
The global injectable drug delivery market, in terms of value, is projected to reach USD 624.50 billion by 2021 from USD 362.38 billion in 2016, at a CAGR of 11.5% during the forecast period. The increase ...